Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CFO Benjamin Hohl sold 3,250 shares of the stock in a transaction on Monday, January 27th. The shares were sold at an average price of $21.59, for a total transaction of $70,167.50. Following the sale, the chief financial officer now directly owns 13,000 shares of the company's stock, valued at $280,670. The trade was a 20.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Benjamin Hohl also recently made the following trade(s):
- On Friday, January 3rd, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $25.04, for a total transaction of $25,040.00.
- On Monday, December 30th, Benjamin Hohl sold 900 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.51, for a total transaction of $20,259.00.
- On Friday, December 27th, Benjamin Hohl sold 3,350 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.15, for a total transaction of $74,202.50.
- On Wednesday, November 27th, Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $24.89, for a total transaction of $130,672.50.
Enliven Therapeutics Price Performance
Enliven Therapeutics stock traded down $0.18 during trading hours on Wednesday, reaching $20.86. The stock had a trading volume of 326,656 shares, compared to its average volume of 275,742. The company has a market cap of $1.02 billion, a price-to-earnings ratio of -10.98 and a beta of 1.04. The business's 50 day moving average price is $23.27 and its 200-day moving average price is $24.33. Enliven Therapeutics, Inc. has a 52 week low of $10.90 and a 52 week high of $30.03.
Wall Street Analysts Forecast Growth
A number of equities analysts recently issued reports on ELVN shares. BTIG Research began coverage on shares of Enliven Therapeutics in a report on Friday, December 13th. They issued a "buy" rating and a $42.00 price objective on the stock. HC Wainwright reiterated a "buy" rating and set a $37.00 price objective on shares of Enliven Therapeutics in a research report on Tuesday, October 1st. Finally, Robert W. Baird lifted their price objective on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the company an "outperform" rating in a research report on Friday, November 15th. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Enliven Therapeutics presently has a consensus rating of "Buy" and an average price target of $38.25.
Check Out Our Latest Analysis on Enliven Therapeutics
Institutional Investors Weigh In On Enliven Therapeutics
Several hedge funds have recently added to or reduced their stakes in the business. FMR LLC boosted its stake in shares of Enliven Therapeutics by 10.6% during the 3rd quarter. FMR LLC now owns 6,296,179 shares of the company's stock worth $160,804,000 after acquiring an additional 601,611 shares in the last quarter. Janus Henderson Group PLC increased its holdings in shares of Enliven Therapeutics by 43.0% during the 3rd quarter. Janus Henderson Group PLC now owns 1,041,724 shares of the company's stock worth $26,611,000 after buying an additional 313,019 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Enliven Therapeutics by 9.9% during the 3rd quarter. Geode Capital Management LLC now owns 750,208 shares of the company's stock worth $19,164,000 after buying an additional 67,813 shares during the last quarter. State Street Corp increased its holdings in shares of Enliven Therapeutics by 2.9% during the 3rd quarter. State Street Corp now owns 745,944 shares of the company's stock worth $19,051,000 after buying an additional 21,018 shares during the last quarter. Finally, First Turn Management LLC boosted its position in shares of Enliven Therapeutics by 29.5% during the 3rd quarter. First Turn Management LLC now owns 535,092 shares of the company's stock worth $13,666,000 after purchasing an additional 121,849 shares during the period. 95.08% of the stock is owned by hedge funds and other institutional investors.
About Enliven Therapeutics
(
Get Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Enliven Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enliven Therapeutics wasn't on the list.
While Enliven Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
